These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24262439)

  • 1. Trastuzumab: qui bono?
    Krop IE; Burstein HJ
    J Natl Cancer Inst; 2013 Dec; 105(23):1772-5. PubMed ID: 24262439
    [No Abstract]   [Full Text] [Related]  

  • 2. Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.
    Pogue-Geile KL; Kim C; Jeong JH; Tanaka N; Bandos H; Gavin PG; Fumagalli D; Goldstein LC; Sneige N; Burandt E; Taniyama Y; Bohn OL; Lee A; Kim SI; Reilly ML; Remillard MY; Blackmon NL; Kim SR; Horne ZD; Rastogi P; Fehrenbacher L; Romond EH; Swain SM; Mamounas EP; Wickerham DL; Geyer CE; Costantino JP; Wolmark N; Paik S
    J Natl Cancer Inst; 2013 Dec; 105(23):1782-8. PubMed ID: 24262440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human epidermal growth factor receptor 2 testing recommendation.
    Raji A; Lurie RH
    Arch Pathol Lab Med; 2007 Sep; 131(9):1330-1; author reply 1331-3. PubMed ID: 17824785
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors.
    Tuma RS
    J Natl Cancer Inst; 2012 Jul; 104(13):968-9. PubMed ID: 22745473
    [No Abstract]   [Full Text] [Related]  

  • 5. Meningeal carcinomatosis in HER2-overexpressing breast cancers.
    Bidard FC; Guilhaume MN; Gauthier H; Cottu PH; Diéras V; Pierga JY
    J Neurooncol; 2009 Jun; 93(2):287-8. PubMed ID: 19139826
    [No Abstract]   [Full Text] [Related]  

  • 6. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
    Cho WC; Roukos DH
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiac toxicity monitoring for HER2-positive breast cancer patients undergoing trastuzumab therapy: are we doing enough?
    Gujral DM; Lloyd G; Bhattacharyya S
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):446-7. PubMed ID: 23583229
    [No Abstract]   [Full Text] [Related]  

  • 8. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeted Therapies in the Treatment of Breast Cancer. Proceedings of a meeting. Kailua-Kona, Hawaii, July 19-23, 2000.
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):1-153; quiz 154-65. PubMed ID: 11760720
    [No Abstract]   [Full Text] [Related]  

  • 10. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
    Huang Y; Fu P; Fan W
    Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas.
    Rodrigues MJ; Albiges-Sauvin L; Wassermann J; Cottu PH
    Ann Oncol; 2011 Nov; 22(11):2530. PubMed ID: 21700734
    [No Abstract]   [Full Text] [Related]  

  • 13. The promise of antibody-drug conjugates.
    Teicher BA; Doroshow JH
    N Engl J Med; 2012 Nov; 367(19):1847-8. PubMed ID: 23134386
    [No Abstract]   [Full Text] [Related]  

  • 14. HER2-positive breast cancer: a new piece of the puzzle.
    Gnant M; Bartsch R; Steger GG
    Lancet Oncol; 2014 Jun; 15(7):668-9. PubMed ID: 24793817
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff.
    Duchnowska R; Sperinde J; Chenna A; Haddad M; Paquet A; Lie Y; Weidler JM; Huang W; Winslow J; Jankowski T; Czartoryska-Arłukowicz B; Wysocki PJ; Foszczyńska-Kłoda M; Radecka B; Litwiniuk MM; Zok J; Wiśniewski M; Zuziak D; Biernat W; Jassem J
    Clin Cancer Res; 2014 May; 20(10):2805-13. PubMed ID: 24668646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experts debate value of HER2 testing methods.
    Nelson NJ
    J Natl Cancer Inst; 2000 Feb; 92(4):292-4. PubMed ID: 10675369
    [No Abstract]   [Full Text] [Related]  

  • 17. Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
    Seidman AD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):178-9. PubMed ID: 16596138
    [No Abstract]   [Full Text] [Related]  

  • 18. Will single-time tumor profiling and a "guilt by association" approach allow us to outsmart HER2-positive breast cancer?
    Arteaga CL
    Clin Cancer Res; 2007 Feb; 13(4):1071-3. PubMed ID: 17317812
    [No Abstract]   [Full Text] [Related]  

  • 19. Ado-trastuzumab emtansine approved for advanced breast cancer.
    Traynor K
    Am J Health Syst Pharm; 2013 Apr; 70(7):562. PubMed ID: 23515502
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab.
    Campiglio M; Sandri M; Sasso M; Bianchi F; Balsari A; Ménard S; Tagliabue E
    Ann Oncol; 2014 May; 25(5):1073-4. PubMed ID: 24558025
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.